Supreme Court asked to keep abortion drug mifepristone available by mail WASHINGTON – Two years after the Supreme Court tossed out a challenge to the widely used abortion drug mifepristone, the justices must again decide whether access should be restricted. In an emergency filing on May 2, mifepristone maker Danco Laboratories asked the court to immediately pause a lower court ruling limiting access. Circuit Court of Appeals on May 1 temporarily reinstated a Food and Drug Administration requirement that doctors prescribe the drug only after an in-person exam. The three-judge panel did so in response to a challenge from Louisiana to the elimination of that requirement by the Biden administration.
Latest development
Media Coverage · May 2, 2026
A response was filed.
newspaper Read articleSupreme Court asked to keep abortion drug mifepristone available by mail WASHINGTON – Two years after the Supreme Court tossed out a challenge to the widely used abortion drug mifepristone, the justices must again decide whether access should be restricted. In an emergency filing on May 2, mifepristone maker Danco Laboratories asked the court to immediately pause a lower court ruling limiting access. Circuit Court of Appeals on May 1 temporarily reinstated a Food and Drug Administration requirem
Open original open_in_newJuryvine summaries are generated from court records. Expand "Source" on any row to see the underlying filing.
A response was filed.
Supreme Court asked to keep abortion drug mifepristone available by mail WASHINGTON – Two years after the Supreme Court tossed out a challenge to the widely used abortion drug mifepristone, …
Sources tracked
1 outlet · 1 article
Timeline events
1 record on file
Last updated
2 days, 13 hours ago
Juryvine aggregates docket entries from PACER/CourtListener, press coverage, and GDELT signals. Ingestion timestamps do not appear in the What Changed feed — that reflects real court activity only.